FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

• click to rate

  Posted by Two Blokes Jun 24 - Filed in Stock - 2 views
  
  Capricor Therapeutics Inc CAPR on Tuesday provided regulatory updates related to its Biologics License Application (BLA) for Deramiocel, the company's lead cell therapy candidate for the treatment of Duchenne Muscular Dystrophy (DMD)—associated cardiomyopathy.